Characteristics of human immunodeciency virus-1 infected children receiving Highly active antiretroviral therapy: A cross-sectional study;Características de niños con infección por virus de la inmunodeficiencia humana-1 que reciben tratamiento antirretroviral de gran actividad: estudio de corte transversal

Anales de Pediatria

Volumn 76, Issue 6, 2012, Pages 317-323

  Badillo, K ^a   Prieto, L ^a   Toledano, M ^a   Guillen, S ^a   Alvarez A ^a   Garcia Bermejo I ^a   Ramos Amador, J T ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

Highly active antiretroviral therapy; Human immunodeciency virus infected children; Immune control; Metabolic toxicity; Virological control

Indexed keywords

DARUNAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TIPRANAVIR;

ADOLESCENT; ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HYPERLIPIDEMIA; LIPODYSTROPHY; VIRUS LOAD;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; MALE; YOUNG ADULT;

EID: 84861794647     PISSN: 16954033     EISSN: 16959531     Source Type: Journal    
DOI: 10.1016/j.anpedi.2011.12.005     Document Type: Article

References (22)

1. K. Patel, M.A. Hernán, P.L. Williams, J.D. Seeger, K. McIntosh, and R.B. Van Dyke Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV Infection: A 10-Year Follow-Up Study Clin Infect Dis 46 2008 507 515
2. C. Palladino, J.M. Bellón, I. Jarrín, M.D. Gurbindo, M.I. De José, and J.T. Ramos Impact of highly active antiretroviral therapy (HAART) on AIDS and death in a cohort of vertically HIV type 1 infected children: 1980-2006 AIDS Res Hum Retroviruses 11 2009 1091 1097
3. J.M. Sánchez, J.T. Ramos Amador, S. Fernández de Miguel, M.I. González Tomé, P. Rojo Conejo, and P. FerrandoVivas Impact of highly active antiretroviral therapy on the morbidity and mortality in Spanish human immunodeficiency virus-infected children Pediatr Infect Dis J 22 2003 863 867
4. E.M. Connor, R.S. Sperling, R. Gelber, P. Kiselev, G. Scott, and M.J. O'Sullivan Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group N Engl J Med 331 1994 1173 1180
5. I. Solis, E. Muñoz, J.T. Ramos, M.I. González-Tomé, X. Rojano, and J. Almeda Características maternas en una cohorte de gestantes con infección por el VIH-1 Med Clin (Barc) 127 2006 121 125
6. Vigilancia epidemiológica del sida en España- Registro nacional de casos de sida [consultado 15 Mayo 2011]. Disponible en: http://www.isciii.es/htdocs/centros/epidemiologia/pdf/SPNS-Informe-semestral.pdf
7. Informe sobre la pandemia mundial de sida. Programa Conjunto de las Naciones Unidas sobre el VIH/sida (ONUSIDA) y la Organización Mundial de la Salud (OMS) [consultado 15 Mayo 2011]. Disponible en: http://whqlibdoc.who. int/unaids/2008/9789291737130-spa.pdf
8. A. Judd, K. Doerholt, P.A. Tookey, M. Sharland, A. Riordan, and E. Menson Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care Clin Infect Dis 45 2007 918 924
9. E.G. Leonard, and G.A. McComsey Metabolic complications of antirretroviral therapy in children Pediatr Infect Dis J 22 2003 77 84
10. J.T. Ramos, and M.J. Mellado Actualización en el tratamiento antirretroviral en la infección por el virus de la inmunodeficiencia humana An Pediatr (Barc) 60 2004 254 261
11. A. Faye. New challenges in therapeutic management of human immunodeficiency virus-infected children Arch Pediatr 14 2007 212 218
12. M.T. Varela, I.C. Salazar, and D. Correa Adherencia al tratamiento en la infección por VIH/SIDA. Consideraciones teóricas y metodológicas para su abordaje Acta Colombiana de Psicología 11 2008 101 113
13. Centers for Disease Control, Prevention (CDC) 1993 revised classification system for human immunodeficiency virus infection in children less than 13 years of age MMWR 43 n. RR-12 1994 1 15
14. PENTA Steering Committee, Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Medicine. 2009;10:591-613. [consultado 1/12/2011]. Disponible en: http://www.pentatrials. org/HIV-759.pdf
15. D.M. Gibb, R.L. Goodall, V. Giacomet, L. McGee, A. Compagnucci, and H. Lyall Paediatric European Network for Treatment of AIDS Steering Committee. Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial Pediatr Infect Dis J 22 2003 56 62
16. Melvin D, Jungmann E, Foster C, Edwards S, Clapson M, Gardiner K, et al. Supporting change: Successful transition for young people who have grown up with HIV infection. Guidance for practice. [consultado 25/5/2011]. Disponible en http://www.chiva.org.uk/publications/2007/transition.pdf
17. L. Galli, D. Puliti, E. Chiappini, C. Gabiano, P.A. Tovo, and P. Pezzotti Lower mother-to-child HIV-1 transmission in boys is independent of type of delivery and antiretroviral prophylaxis: the Italian Register for HIV Infection in Children J Acquir Immune Defic Syndr 40 2005 479 485
18. C.D. Mitchell HIV-1 encephalopathy among perinatally infected children: Neuropathogenesis and response to highly active antiretroviral therapy Ment Retard Dev Disabil Res Rev 12 2006 216 222
19. Recomendaciones CEVIHP, SEIP, AEP, PNS, respecto al tratamiento antirretroviral en niños y adolescentes infectados por el virus de la inmunodeficiencia humana (VIH) [consultado 25 Mayo 2011]. Marzo 2008. Disponible en: http://www.msc.es/ciudadanos/enfLesiones/enfTransmisibles/sida/docs/ guiasAntirretroviral-ninosAdolescentes2008.pdf
20. S. Welch, M. Sharland, E.G. Lyall, G. Tudor-Williams, T. Niehues, U. Wintergerst on behalf of the PENTA Steering Committee PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection HIV Med 10 2009 591 613
21. R. Thiébaut, V. Daucourt, P. Mercié, D.K. Ekouévi, D. Malvy, and P. Morlat Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: AquitaineCohort, France, 1999. Groupe d'Epidémiologie Clinique du Syndrome d'Immunodéficience Acquise en Aquitaine Clin Infect Dis 31 2000 1482 1487
22. E.G. Leonard, and G.A. McComsey Antiretroviral therapy in HIV-infected children: the metabolic cost of improved survival Infect Dis Clin North Am 19 2005 713 729